L. Schiller

[Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms].

R. Greil, M. Fiegl, R. Pirker, 2007, Wiener klinische Wochenschrift.

Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer.

H. Samonigg, P. Sevelda, H. Hausmaninger, 1989, Onkologie.

CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.

H. Hausmaninger, M. Fridrik, M. Neubauer, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer.

C. Marth, B. Eibl, D. Niederwieser, 1996, Blood.

Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphoma.

A. Chott, H. Hausmaninger, M. Fridrik, 1998, European journal of cancer.

Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer.

H. Samonigg, P. Sevelda, H. Hausmaninger, 1995, European journal of cancer.